logo
20 Leadership Red Flags: How To Know A Founder Isn't Ready To Scale

20 Leadership Red Flags: How To Know A Founder Isn't Ready To Scale

Forbes23-06-2025
The ability to scale a startup hinges as much on leadership maturity as it does on market opportunity. Founders who micromanage, resist feedback or avoid tough decisions often stall progress—not because the business lacks potential, but because the leader hasn't adapted to what growth really requires.
Scaling means letting go of control, building trust in others and shifting from instinct to strategy. Below, Forbes Coaches Council members share 20 leadership red flags that signal when a founder's mindset may be holding the business back.
1. Inability To Delegate
If a founder says 'I'll just do it myself' too often, run. That lone-wolf mindset kills scale. Real growth needs delegation, trust and systems. If you can't let go, your startup stays stuck. Scaling is a team sport—not a solo mission. - Anastasia Paruntseva, Visionary Partners Ltd.
2. Believing They're The Only One Who Can Do It Right
One red flag when scaling a startup is what I call egocentric thinking. This occurs when a leader insists on delegating and controlling every aspect of their business because they believe they are the most knowledgeable and/or capable person to do the job. This mindset will always make it difficult for an individual to scale their business because they will be restricted by time. - Andrea Bullard, Andrea Bullard & Company
3. Staying Tactical Instead Of Leading Strategically
A key red flag is staying stuck in tactical mode and failing to transition into a strategic role. Early on, being hands-on is necessary, but scaling requires a shift. Founders must empower their teams to take ownership of execution while they focus on strategy. If they can't let go or trust others, they risk becoming the bottleneck. Scaling up means leveling up your leadership. - Kiran Mann, M2M Business Solutions Inc.
4. Failing To Make Timely Decisions
Indecision can destroy a startup. Decisions must be made quickly. Founders must have the ability to assess risks, benefits and alternatives. They must be agile, think on their feet and adapt. Any decision is better than no decision. - Sunny Smith, Empowering Women Physicians
Forbes Coaches Council is an invitation-only community for leading business and career coaches. Do I qualify?
5. Rejecting Outside Feedback
Researchers have estimated that only 8 percent of people worldwide possess the right mix of personality traits for startup success, so most will need to be able to work effectively with others if they want to scale. Refusing outside feedback or getting stuck in a 'my way or the highway' mindset suggests that someone isn't ready. Sure, it may work for some entrepreneurs, but not all of us are Steve Jobs! - Megan Malone, Truity
6. Expecting Others To Blindly Follow Them
A clear red flag is when a leader criticizes others for not doing things exactly as they do. This mindset stifles creativity, trust and team development. Effective leaders recognize that different doesn't mean wrong. Empower your team to use their own strengths and approaches—this diversity is what truly drives innovation and helps carry out the vision. - Dr. Marita Kinney, BCC, Msc.D, Pure Thoughts Publishing and Wellness
7. Lacking A Transferable Vision
If a leader can't clearly articulate their vision, expectations or processes well enough to hand them off—like in a playbook that someone else could easily follow and execute—they're not ready to scale. Until the vision in their head becomes something others can understand, contribute to and carry forward without constant oversight, they won't be able to let go or build a team that grows with them. - Kelly Stine, The Leading Light Coach
8. Neglecting Team Development
One red flag is a leader's inability to be a 'people developer.' If an entrepreneur does not prioritize people and create a culture of learning and development, that startup will remain a startup. - Edward Doherty, One Degree Coaching, LLC
9. Dismissing Advice From Allies
If a founder is resistant to advice from their team and/or from their most aligned investors, that is a red flag. It's important for the founder to be the activist pushing the product or service into the world, but they need to build coalitions and learn from others who have seen similar launches. A growth mindset is a must. - Katy MacKinnon Hansell, Katy Hansell Impact Partners
10. Holding On Too Tightly As An Owner-Operator
Scaling means that things will change, and leaders will need to empower others to move things forward. Leaders who speak about themselves as the brand and how they need to position themselves as the face of the organization haven't yet made the mindset shift. It's the difference between being an owner-operator and being an owner. The owner's mindset is ready to scale. - Kristy Busija, Next Conversation Consulting
11. Staying Stuck In The Startup Mentality
A key red flag is a leader who continues to operate with a startup mindset, relying on instinct, individual effort and constant pivots. Scaling requires a shift to systemic leadership, which involves developing people, building processes and focusing on a few high-impact ideas. If the founder can't make this transition, they'll need to bring in someone who can, or risk jeopardizing successful growth. - Gabriella Goddard, Brainsparker Ltd
12. Failing To Attract A Shared Vision
If you want to scale your startup, one thing leadership must do is establish a vision that attracts the right people. Creating a vision and purpose allows you to find your community: those who share your beliefs and want to be part of the journey. This goes for team members, customers and other stakeholders. You can't become a true leader if you have no one willing to follow you. - Robert Gauvreau, Gauvreau | Accounting Tax Law Advisory
13. Avoiding Hard Conversations
Neuroleadership shows that the brain craves certainty, but growth demands embracing uncertainty and social discomfort. Leaders must train their prefrontal cortex to stay calm under pressure and turn tough feedback into adaptive learning. Scaling starts there. - Adam Levine, InnerXLab
14. Making Themselves Indispensable
One red flag is the 'indispensability complex'—when founders create bottlenecks by remaining central to every decision. I watched a promising fintech company collapse when its CEO couldn't evolve from doer to enabler. Scaling demands leaders who derive satisfaction from team achievements rather than personal heroics. The most dangerous founders secretly fear becoming irrelevant in their own creation. - Nirmal Chhabria
15. Prioritizing Activity Over Long-Term Planning
A red flag I have witnessed regularly is when the founder or leader confuses hustle with strategy. If a leader's main tool is working harder—not thinking smarter—they're not ready to scale. Startups grow sustainably when founders step out of the weeds and start building for the long game, not just surviving the week. - Arthi Rabikrisson, Prerna Advisory
16. Blame-Shifting As A Leader
As John Maxwell says, 'Everything rises and falls on leadership.' When a founder avoids responsibility and constantly blames others, they're not ready to scale. A leader who's ready says, 'If there's a problem, I own it. If there's a win, I share it with the team.' That mindset builds trust and momentum and shows you're ready to grow. - Sandra Balogun, The CPA Leader
17. Overlooking The Emotional Side Of Growth
A red flag is the absence of a systemic plan or personal readiness to manage the change. Scaling isn't just operational, it's emotional. Leaders must prepare themselves, their teams, partners and clients for the realities of growth and change. It's critical to have strong communication systems in place to adapt and solve problems as they arise. - Mel Cidado, Breakthrough Coaching
18. Lack Of Adaptability
If a leader rigidly clings to their initial vision or refuses to consider feedback, they may struggle to navigate the complexities of scaling. In the Marine Corps, I learned the value of being 'Semper Gumby,' meaning 'always flexible.' This adaptability is essential for growth, allowing leaders to evolve alongside their business and its needs. - Jay Garcia, Jay Garcia Group
19. Inability To Control Anger
If a person is quick to become angry, they are not ready for leadership. Anger is a distancing emotion that can hinder one's ability to build trust and alliances—two core skills essential for a business owner. Explosive anger usually indicates unresolved emotional issues from the past. Anger is generally unhealthy and unnecessary in the workplace. - Bill English, OnPath Coaching
20. Lack Of Self-Awareness
One flaw to look for is whether a founder is self-aware. As a key component of emotional intelligence, knowing your own strengths and weaknesses is critical for leaders to learn quickly from experimentation and pivot as needed to put their firms on a growth trajectory. By lacking a growth mindset and self-awareness, leaders can be trapped by blind spots and office politics. - Kelly Huang, Coach Kelly Huang
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets

Yahoo

time9 minutes ago

  • Yahoo

Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets

Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Snap Stock Plunged After Earnings. Buy the Dip?
Snap Stock Plunged After Earnings. Buy the Dip?

Yahoo

time9 minutes ago

  • Yahoo

Snap Stock Plunged After Earnings. Buy the Dip?

Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time9 minutes ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store